ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study
| Autor: | Erhan Babalik, Ismail Mihmanli, Sadık Toprak, Evin Bozcali, Solen Himmetoglu |
|---|---|
| Přispěvatelé: | Zonguldak Bülent Ecevit Üniversitesi |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Endothelium Brachial Artery Vasodilator Agents Isosorbide Dinitrate medicine.disease_cause Placebo Gastroenterology endothelial dysfunction law.invention Randomized controlled trial Double-Blind Method law Internal medicine Cardiac syndrome X Malondialdehyde Fatty Acids Omega-3 Medicine Humans coronary resistance Microvascular Angina Ultrasonography chemistry.chemical_classification business.industry Fatty acid lipid peroxidation General Medicine Middle Aged medicine.disease Clinical trial Vasodilation Oxidative Stress medicine.anatomical_structure Treatment Outcome chemistry Female Endothelium Vascular Isosorbide dinitrate Cardiology and Cardiovascular Medicine business Oxidative stress medicine.drug |
| Zdroj: | Coronary artery disease. 24(4) |
| ISSN: | 1473-5830 |
| Popis: | WOS: 000318154600011 PubMed: 23425772 Objective We conducted a clinical trial to examine the effect of omega-3 fatty acids in patients with cardiac syndrome X (CSX). We aimed to evaluate the potential impact of omega-3 fatty acids on endothelial function, oxidative stress, and symptom relief in the CSX. Methods and results Eighteen patients with CSX were enrolled according to a double-blind, randomized, placebo-controlled design. Patients were randomized to omega-3 fatty acids (1440 mg/day, n = 8) or placebo (n = 10) for 4 months. We assessed plasma levels of malondialdehyde (MDA), endothelium-dependent vasodilatation [flow-mediated dilatation (FMD)], endothelium-independent vasodilatation [nitroglycerin-mediated dilatation (NMD)], and status of symptom [score with Seattle Angina Questionnaire (SAQ)] before and after the treatment. After 4 months, patients who were treated with omega-3 fatty acids showed significant increases in the FMD (from 47 +/- 48 to 104 +/- 23%, P Turkish Society of Cardiology [2006-3]; Kocak Farma Pharmaceutical Company, Istanbul, Turkey This study was supported by a Research Fund of the Turkish Society of Cardiology (fund number 2006-3) and Kocak Farma Pharmaceutical Company, Istanbul, Turkey. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|